Loading
Lung Cancer Research Studies · Journal article
Medicine · August 14, 2026
Encouraging direction, but not yet definitive.
This retrospective two-center study of 64 advanced SCLC patients receiving first-line chemoimmunotherapy found that a high lactate dehydrogenase-to-lymphocyte ratio (LLR >471.5) independently predicted shorter overall survival and progression-free survival on univariate and multivariate analysis. The LLR may serve as a cost-effective prognostic tool integrable into routine blood work, but the small sample size, retrospective design, and lack of prospective validation limit current clinical utility.
Retrospective two-center cohort study. 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC receiving first-line chemoimmunotherapy at 2 university hospitals in Japan. Intervention: Platinum-etoposide plus PD-L1 inhibitor as first-line therapy. Compared with: High LLR (>471.5) versus low LLR; also compared LLR to NLR and PLR. n = 64. 2 university hospitals in Japan.
10 of 64 patients (16%) had high LLR >471.5; high LLR group had significantly shorter OS and PFS 56 patients (87.5%) experienced progressive disease and 36 (56.3%) died by data cutoff High LLR was an independent predictor of worse OS and PFS on multivariate analysis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated prospectively, LLR could provide clinicians a simple, inexpensive blood-based prognostic marker for risk stratification in advanced SCLC. Current evidence supports exploration in larger cohorts but does not yet justify clinical adoption as a standalone prognostic tool.
A real result from a sound but limited retrospective study showing LLR predicts OS and PFS in advanced SCLC, but small sample size, single disease context, and lack of prospective validation limit immediate clinical application.
As stated by the source record.
Quoted from the source exactly as published.
If validated prospectively, LLR could provide clinicians a simple, inexpensive blood-based prognostic marker for risk stratification in advanced SCLC. Current evidence supports exploration in larger cohorts but does not yet justify clinical adoption as a standalone prognostic tool.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyte ratio (LLR) is a potential indicator of tumor metabolism and host immune response; a high LLR is correlated with a poor prognosis in other carcinomas. The LLR may be a more comprehensive indicator of prognosis than the neutrophil-lymphocyte ratio (NLR) or platelet-lymphocyte ratio (PLR), which mainly reflect host immune status. This study evaluates the prognostic value of the LLR in patients with SCLC receiving first-line chemoimmunotherapy. This retrospective, two-center study was conducted at 2 university hospitals in Japan and analyzed 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC who received platinum-etoposide plus a PD-L1 inhibitor as first-line therapy between August 2019 and December 2023. The LLR, NLR, and PLR were calculated from blood tests immediately before the start of first-line therapy, and cutoff values were set using the X-tile software. The prognostic significance of these markers was assessed using Kaplan–Meier survival analysis and the Cox proportional hazards model. Of the 64 patients included, 10 (16%) had high LLR (>471.5). The median duration of observation was 10.5 months (interquartile range: 6.0–19.0 months); by the time of data cutoff, 56 patients (87.5%) had experienced progressive disease and 36 (56.3%) had died. The high LLR group had significantly shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis was performed using only those factors (LLR/ECOG PS/bone metastasis regarding OS and LLR/bone metastasis regarding PFS) identified as significant in univariate analyses. A high LLR was an independent predictor of worse OS and PFS. While the NLR was an independent prognostic factor for OS, neither NLR nor PLR was a significant predictor of PFS. The LLR is a novel potential prognostic biomarker that integrates tumor metabolism and host immunity in patients with SCLC receiving first-line chemoimmunotherapy. Because it can be readily calculated from routine blood tests, it may serve as a cost-effective tool for risk stratification. However, further prospective validation in larger cohorts is warranted.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.